Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	€0.0550	0.00%	0
23/07/26	€0.0550	0.00%	0
22/07/26	€0.0550	0.00%	0
21/07/26	€0.0550	0.00%	95
20/07/26	€0.0550	0.00%	0

End-of-day quote Deutsche Boerse AG

More quotes

End-of-day quote Deutsche Boerse AG Other stock markets 23/07/2026			5-day change	1st Jan Change
0.0550 ^EUR	0.00%		0.00%	+316.67%

Market Cap	144K 164K 134K 123K 231K 15.8M 235K 1.59M 622K 7.77M 616K 603K 26.86M	P/E 2021	-3.89x	P/E 2022	-53x
Enterprise Value	9.87M 11.23M 9.18M 8.42M 15.82M 1.08B 16.07M 109M 42.57M 532M 42.17M 41.26M 1.84B	EV / Sales 2021	14.1x	EV / Sales 2022	1.22x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

Current month	-9.84%
1 month	+1.85%
3 months	+23.60%
6 months	+323.08%
Current year	+316.67%

1 week	0.06	0.06
1 month	0.05	0.09
Current year	0.01	0.23
1 year	0	0.23
3 years	0	6.1
5 years	0	20.15
10 years	0	36.78

Manager	Title	Age	Since
Tilmann Bur CEO	Chief Executive Officer	62	01/09/2023
Sebastian Werner DFI	Director of Finance/CFO	-	01/06/2022

Paion AG Stock

Stocks

PA8K

DE000A3E5EG5

Biotechnology & Medical Research

Valuation: Paion AG

Chart: Paion AG

Latest news : Paion AG

Press Releases: Paion AG

News in other languages: Paion AG

Quotes and Performance

Course Extremes

Managers and Directors: Paion AG

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Director	Title	Age	Since
Karin Louise Dorrepaal BRD	Director/Board Member	65	01/10/2012
Hans Tanner BRD	Director/Board Member	75	01/06/2017
Markus Guilherme Dieken BRD	Director/Board Member	-	22/05/2019

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/27/22 A	Gregor Siebert	Buy	Director	1,121	0.0016%
1/12/21 A	James Phillips	Buy	Chief Executive Officer	8,500	0.0127%
6/8/20 A	James Phillips	Buy	Chief Executive Officer	13,158	0.0202%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PAION AG	0.00%	0.00%	+554.76%	-99.07%	447K
LONZA GROUP AG	+1.07%	-3.49%	-3.25%	+12.87%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+408.41%	+629.49%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+9.93%	+66.92%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+3.60%	-8.81%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+3.37%	+38.15%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+31.97%	+143.53%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	+0.76%	+8.50%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-15.00%	-31.68%	12.7B
Average	+0.20%	+0.75%	+110.51%	+84.43%	24.53B
Weighted average by Cap.	+0.48%	+0.91%	+75.32%	+136.64%

	2021	2022
Net sales	7.13M 8.12M 6.63M 6.08M 11.43M 782M 11.61M 78.72M 30.76M 384M 30.47M 29.81M 1.33B	33.25M 37.85M 30.92M 28.37M 53.31M 3.65B 54.13M 367M 143M 1.79B 142M 139M 6.2B
Net income	-21.79M -24.8M -20.26M -18.59M -34.93M -2.39B -35.47M -241M -93.99M -1.17B -93.12M -91.11M -4.06B	-579K -659K -538K -494K -928K -63.48M -943K -6.39M -2.5M -31.21M -2.47M -2.42M -108M
Net Debt	13.77M 15.68M 12.8M 11.75M 22.08M 1.51B 22.42M 152M 59.41M 742M 58.85M 57.58M 2.57B	9.72M 11.07M 9.04M 8.3M 15.59M 1.07B 15.83M 107M 41.95M 524M 41.56M 40.66M 1.81B